[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100371353":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":33,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":67,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Combined modality",null,"Patients receiving radiotherapy and a molecular agent for the treatment of cancer",[13],"Radiation: Radiotherapy",[15],{"type":16,"name":17,"description":9,"armGroupLabels":18,"otherNames":19},"RADIATION","Radiotherapy",[9],[20],"Anti-neoplastic Molecular Agent",[22],{"name":23,"affiliation":24,"role":25},"Philip Wong, MD","CHUM","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Mom Phat, RN","CONTACT","1-514-8908000","11171","mom.phat.chum@ssss.gouv.qc.ca",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Centre Hospitalier de l'Université de Montréal","RECRUITING","Montreal","Quebec","H2X 0A9","Canada","CA",{"type":43,"coordinates":44},"Point",[45,46],-73.58781,45.50884,{"lat":46,"lon":45},[49,51],{"name":28,"role":29,"phone":50,"phoneExt":31,"email":32},"514-8908000",{"name":23,"role":25,"phone":10,"phoneExt":10,"email":10},{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100371353","attribution-of-toxicities-due-to-radiotherapy-and-immuno-biological-therapies-100371353",false,"NCT04115267","Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies","Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies - Registry","AtTRIBut","Inclusion Criteria:\n\n* Consent to be part of the AtTRIBut registry\n* Prior histological diagnosis of primary cancer.\n* If the patient has metastatic disease, there must be radiological or pathological evidence of metastasis\n* Age\\> 18 years\n* Receiving a molecular therapy\n* Indicated to receive radiotherapy\n* Radiation therapy can be administered using 3D conventional, IMRT or SBRT techniques.\n\nExclusion Criteria:\n\n• Refusal or inability to receive radiotherapy","ALL","18 Years",{"count":65,"type":66},3600,"ESTIMATED","1 Year","OBSERVATIONAL","Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed.",[71,72],"Cancer","Radiotherapy Side Effect",[74,75,76,77,71],"Combined effect","Registry","Side effects","Patient reported outcome","2026-08-13",{"date":80,"type":81},"2026-08-14","ACTUAL",{"date":83,"type":81},"2019-09-13",{"date":85,"type":66},"2030-09-30",{"name":5,"class":6},1]